No profile data available.
Dianthus Therapeutics, Inc. (DNTH) is a healthcare company in the brain and nerve treatment drugs industry, based in New York, United States, with about 92 full-time employees.
It reported revenue of $2.04 million for fiscal year 2025, down 67.3% from fiscal year 2024, and net income of -$162.34 million. Its market capitalization was $4.50 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases.
Dianthus Therapeutics reported $2.04 million in revenue for fiscal year 2025, down 67.3% from $6.24 million in fiscal year 2024.
$4.50 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include PTC Therapeutics, Inc. (PTCT), Scholar Rock Holding Corporation (SRRK), Praxis Precision Medicines, Inc. (PRAX), Acadia Pharmaceuticals Inc. (ACAD).